Rufinamide (original) (raw)
Rufinamid (Handelsname Inovelon®) ist ein krampfunterdrückender Arzneistoff, der in der Behandlung des Lennox-Gastaut-Syndroms, einer besonders schwer verlaufenden Form der Epilepsie, eingesetzt wird. Es ist nur zur Zusatztherapie ab dem vierten Lebensjahr zugelassen.
| Property | Value |
|---|---|
| dbo:abstract | Rufinamid (Handelsname Inovelon®) ist ein krampfunterdrückender Arzneistoff, der in der Behandlung des Lennox-Gastaut-Syndroms, einer besonders schwer verlaufenden Form der Epilepsie, eingesetzt wird. Es ist nur zur Zusatztherapie ab dem vierten Lebensjahr zugelassen. (de) Rufinamida (Inovelon ®) es un agente anticonvulsivante, especialmente indicado en el síndrome de Lennox-Gastaut, una variedad de epilepsia. Es una terapia adicional autorizada desde el cuarto año de vida. (es) Rufinamide is an anticonvulsant medication. It is used in combination with other medication and therapy to treat Lennox–Gastaut syndrome and various other seizure disorders. Rufinamide, a triazole derivative, was developed in 2004 by Novartis Pharma, AG, and is manufactured by Eisai. Rufinamide was approved by the US Food and Drug Administration (FDA) in November 2008, as adjunctive treatment of seizures associated with Lennox-Gastaut syndrome in children four years and older and adults. Its official FDA-approved labeling does not mention use in the treatment of partial seizures inasmuch as clinical trials submitted to the FDA were marginal. However, several recent clinical trials suggest that the drug has efficacy for partial seizures It is marketed under the brand name Banzel. It is also marketed in the European Union under the brand name Inovelon. It is available as a generic medication. The mechanism of action of rufinamide is not fully understood. There is some evidence that rufinamide can modulate the gating of voltage-gated sodium channels, a common target for antiepileptic drugs. A recent study indicates subtle effects on the voltage-dependence of gating and the time course of inactivation in some sodium channel isoforms that could reduce neuronal excitability. However, this action cannot explain the unique spectrum of activity of rufinamide. (en) ルフィナミド（Rufinamide）は抗てんかん薬の一つである。レノックス・ガストー症候群の治療について他の抗てんかん薬との併用で用いる旨が承認されている。他の痙攣性発作について承認されている国もある。商品名イノベロン。 ルフィナミドは2008年11月に米国FDAに承認された。日本では2013年3月に承認された。4歳以上の小児および成人に使用できる。2015年2月、米国で1歳〜3歳の小児に対して追加承認された。 (ja) La rufinamide è un farmaco anticonvulsante utilizzato in combinazione con altri farmaci antiepilettici per trattare una rara forma di epilessia chiamata sindrome di Lennox-Gastaut. Lo sviluppo iniziale è stato portato avanti dalla Novartis mentre adesso è prodotto, ulteriormente sviluppato e commercializzato da Eisai. L'Agenzia europea per i medicinali (EMEA) ha approvato la sua immissione in commercio nell'Unione europea il 16 gennaio 2007. (it) |
| dbo:alternativeName | Banzel, Inovelon (en) |
| dbo:bioavailability | 85.000000 (xsd:float) |
| dbo:casNumber | 106308-44-5 |
| dbo:chEMBL | 1201754 |
| dbo:fdaUniiCode | WFW942PR79 |
| dbo:kegg | D05775 |
| dbo:medlinePlus | a609001 |
| dbo:pubchem | 129228 |
| dbo:thumbnail | wiki-commons:Special:FilePath/Rufinamide.svg?width=300 |
| dbo:wikiPageExternalLink | https://druginfo.nlm.nih.gov/drugportal/name/rufinamide |
| dbo:wikiPageID | 6552264 (xsd:integer) |
| dbo:wikiPageLength | 6892 (xsd:nonNegativeInteger) |
| dbo:wikiPageRevisionID | 1124288983 (xsd:integer) |
| dbo:wikiPageWikiLink | dbr:Anticonvulsant dbr:Cytochrome_P450 dbc:Fluoroarenes dbc:Triazoles dbr:Oral_administration dbc:Carboxamides dbc:Sodium_channel_blockers dbr:Food_and_Drug_Administration dbr:Novartis dbr:Lennox–Gastaut_syndrome dbc:Anticonvulsants dbr:Cmax_(pharmacology) dbr:Mechanism_of_action dbr:Triazole dbr:Voltage-gated_sodium_channels dbr:Eisai_Co. dbr:Generic_medication dbr:Seizure_disorder |
| dbp:atcPrefix | N03 (en) |
| dbp:atcSuffix | AF03 (en) |
| dbp:bioavailability | -21600.0 |
| dbp:c | 10 (xsd:integer) |
| dbp:casNumber | 106308 (xsd:integer) |
| dbp:chembl | 1201754 (xsd:integer) |
| dbp:chemspiderid | 114471 (xsd:integer) |
| dbp:dailymedid | Rufinamide (en) |
| dbp:eliminationHalfLife | -36000.0 |
| dbp:excretion | Urine (en) |
| dbp:f | 2 (xsd:integer) |
| dbp:h | 8 (xsd:integer) |
| dbp:iupacName | 1 (xsd:integer) |
| dbp:iupharLigand | 7470 (xsd:integer) |
| dbp:kegg | D05775 (en) |
| dbp:legalStatus | Rx-only (en) |
| dbp:legalUk | POM (en) |
| dbp:legalUs | Rx-only (en) |
| dbp:licenceEu | yes (en) |
| dbp:licenceUs | Rufinamide (en) |
| dbp:medlineplus | a609001 (en) |
| dbp:metabolism | Carboxylesterase-mediated hydrolysis (en) |
| dbp:metabolites | Inactive (en) |
| dbp:n | 4 (xsd:integer) |
| dbp:o | 1 (xsd:integer) |
| dbp:pregnancyAu | B3 (en) |
| dbp:proteinBound | 34.0 |
| dbp:pubchem | 129228 (xsd:integer) |
| dbp:routesOfAdministration | dbr:Oral_administration |
| dbp:smiles | O=CN (en) |
| dbp:stdinchi | 1 (xsd:integer) |
| dbp:stdinchikey | POGQSBRIGCQNEG-UHFFFAOYSA-N (en) |
| dbp:tradename | Banzel, Inovelon (en) |
| dbp:unii | WFW942PR79 (en) |
| dbp:verifiedfields | changed (en) |
| dbp:verifiedrevid | 464384547 (xsd:integer) |
| dbp:watchedfields | changed (en) |
| dbp:wikiPageUsesTemplate | dbt:Cite_web dbt:Distinguish dbt:Drugbox dbt:Portal_bar dbt:Reflist dbt:Short_description dbt:Use_dmy_dates dbt:Cascite dbt:Chemspidercite dbt:Drugbankcite dbt:Ebicite dbt:Fdacite dbt:Stdinchicite dbt:Drugs.com dbt:Anticonvulsants dbt:Channelergics |
| dcterms:subject | dbc:Fluoroarenes dbc:Triazoles dbc:Carboxamides dbc:Sodium_channel_blockers dbc:Anticonvulsants |
| gold:hypernym | dbr:Medication |
| rdf:type | owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 yago:WikicatAnticonvulsants yago:WikicatMolecularFormulas yago:WikicatOrphanDrugs yago:Abstraction100002137 yago:Agent114778436 yago:Anticonvulsant102718469 yago:CausalAgent100007347 yago:Communication100033020 yago:Drug103247620 yago:Formula106816935 yago:Matter100020827 yago:Medicine103740161 yago:Message106598915 yago:MolecularFormula106817173 yago:PhysicalEntity100001930 dbo:Drug yago:Statement106722453 yago:Substance100020090 |
| rdfs:comment | Rufinamid (Handelsname Inovelon®) ist ein krampfunterdrückender Arzneistoff, der in der Behandlung des Lennox-Gastaut-Syndroms, einer besonders schwer verlaufenden Form der Epilepsie, eingesetzt wird. Es ist nur zur Zusatztherapie ab dem vierten Lebensjahr zugelassen. (de) Rufinamida (Inovelon ®) es un agente anticonvulsivante, especialmente indicado en el síndrome de Lennox-Gastaut, una variedad de epilepsia. Es una terapia adicional autorizada desde el cuarto año de vida. (es) ルフィナミド（Rufinamide）は抗てんかん薬の一つである。レノックス・ガストー症候群の治療について他の抗てんかん薬との併用で用いる旨が承認されている。他の痙攣性発作について承認されている国もある。商品名イノベロン。 ルフィナミドは2008年11月に米国FDAに承認された。日本では2013年3月に承認された。4歳以上の小児および成人に使用できる。2015年2月、米国で1歳〜3歳の小児に対して追加承認された。 (ja) La rufinamide è un farmaco anticonvulsante utilizzato in combinazione con altri farmaci antiepilettici per trattare una rara forma di epilessia chiamata sindrome di Lennox-Gastaut. Lo sviluppo iniziale è stato portato avanti dalla Novartis mentre adesso è prodotto, ulteriormente sviluppato e commercializzato da Eisai. L'Agenzia europea per i medicinali (EMEA) ha approvato la sua immissione in commercio nell'Unione europea il 16 gennaio 2007. (it) Rufinamide is an anticonvulsant medication. It is used in combination with other medication and therapy to treat Lennox–Gastaut syndrome and various other seizure disorders. Rufinamide, a triazole derivative, was developed in 2004 by Novartis Pharma, AG, and is manufactured by Eisai. (en) |
| rdfs:label | Rufinamid (de) Rufinamida (es) Rufinamide (it) ルフィナミド (ja) Rufinamide (en) Rufinamida (pt) |
| owl:differentFrom | dbr:Ralfinamide |
| owl:sameAs | freebase:Rufinamide yago-res:Rufinamide wikidata:Rufinamide http://azb.dbpedia.org/resource/روفینامید dbpedia-de:Rufinamide dbpedia-es:Rufinamide dbpedia-fa:Rufinamide dbpedia-it:Rufinamide dbpedia-ja:Rufinamide dbpedia-pt:Rufinamide dbpedia-ro:Rufinamide dbpedia-sh:Rufinamide dbpedia-sr:Rufinamide https://global.dbpedia.org/id/3nLpE |
| prov:wasDerivedFrom | wikipedia-en:Rufinamide?oldid=1124288983&ns=0 |
| foaf:depiction | wiki-commons:Special:FilePath/Rufinamide.svg |
| foaf:isPrimaryTopicOf | wikipedia-en:Rufinamide |
| is dbo:wikiPageRedirects of | dbr:Banzel dbr:C10H8F2N4O dbr:ATC_code_N03AF03 dbr:ATCvet_code_QN03AF03 dbr:Inovelon |
| is dbo:wikiPageWikiLink of | dbr:Anticonvulsant dbr:Banzel dbr:Eisai_(company) dbr:C10H8F2N4O dbr:Lennox–Gastaut_syndrome dbr:ATC_code_N03AF03 dbr:ATCvet_code_QN03AF03 dbr:ATC_code_N03 dbr:Lacosamide dbr:Malignant_migrating_partial_seizures_in_infancy dbr:Inovelon dbr:List_of_drugs:_Rf–Rz |
| is owl:differentFrom of | dbr:Ralfinamide |
| is foaf:primaryTopic of | wikipedia-en:Rufinamide |
